Journal of Neurology

, Volume 261, Issue 3, pp 579–588 | Cite as

Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy

  • Gyri Veiby
  • Anne Kjersti Daltveit
  • Bernt A. Engelsen
  • Nils Erik Gilhus
Original Communication

Abstract

The primary aim of this study was to assess the risks of fetal growth restriction and birth defects in children exposed prenatally to newer and older antiepileptic drugs, using an unselected epilepsy cohort. Deliveries recorded in the compulsory Medical Birth Registry of Norway 1999–2011 formed the study population. All 2,600 children exposed to antiepileptic drugs during pregnancy were compared to all 771,412 unexposed children born to women without epilepsy. Children of untreated mothers with epilepsy served as an internal control group. The main outcomes were small for gestational age birth weight and head circumference, and major congenital malformations. Children exposed to antiepileptic drugs had a moderate risk of growth restriction. Infants exposed to topiramate had a considerable risk of microcephaly (11.4 vs. 2.4 %; OR 4.8; CI 2.5–9.3) and small for gestational age birth weight (24.4 vs. 8.9 %; OR 3.1; 95 % CI 1.9–5.3). Carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, gabapentin, and pregabalin had low malformation rates, whereas topiramate tended to have an elevated malformation rate. Valproate monotherapy was associated with a significant risk of birth defects (6.3 vs. 2.9 %; OR 2.5; CI 1.6–3.8), and specifically with septal heart defects and hypospadias. For mothers using valproate, the presence of major birth defect in one child was associated with a markedly increased risk for the siblings (42.9 vs. 6.7 %; OR 10.4; CI 2.3–46.7). Children of untreated mothers with epilepsy had malformation risk similar to the reference group. In conclusion, topiramate was associated with a substantial risk of fetal growth restriction, and possibly an increased malformation rate. Other newer-generation antiepileptic drugs had a low malformation rate. Valproate monotherapy had a significant malformation risk, especially in repeated pregnancies.

Keywords

Antiepileptic drugs Pregnancy Birth defects Microcephaly Birth weight 

Notes

Conflicts of interest

Dr Veiby has received travel support from UCB Pharma and lecture fees from GlaxoSmithKline. Dr Engelsen has received travel support from GlaxoSmithKline and lecture fees from Lundbeck. Authors Gilhus and Daltveit have no conflicts of interest.

Supplementary material

415_2013_7239_MOESM1_ESM.pdf (433 kb)
Supplementary material 1 (PDF 433 kb)

References

  1. 1.
    Veiby G, Daltveit AK, Engelsen BA, Gilhus NE (2009) Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 50(9):2130–2139CrossRefPubMedGoogle Scholar
  2. 2.
    Harden CL, Meador KJ, Pennell PB, Hauser WA, Gronseth GS, French JA et al (2009) Practice parameter update: management issues for women with epilepsy–focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 73(2):133–141PubMedCentralCrossRefPubMedGoogle Scholar
  3. 3.
    Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A et al (2011) Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10(7):609–617CrossRefPubMedGoogle Scholar
  4. 4.
    Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M et al (2009) Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 360(16):1597–1605PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Meador KJ, Baker GA, Browning N, Cohen MJ, Clayton-Smith J, Kalayjian LA et al (2011) Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 134(Pt 2):396–404PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Meador KJ, Baker GA, Browning N, Cohen MJ, Bromley RL, Clayton-Smith J et al (2012) Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 78(17):1207–1214PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Nadebaum C, Anderson VA, Vajda F, Reutens DC, Barton S, Wood AG (2011) Language skills of school-aged children prenatally exposed to antiepileptic drugs. Neurology 76(8):719–726CrossRefPubMedGoogle Scholar
  8. 8.
    Thomas SV, Sukumaran S, Lukose N, George A, Sarma PS (2007) Intellectual and language functions in children of mothers with epilepsy. Epilepsia 48(12):2234–2240PubMedGoogle Scholar
  9. 9.
    Vinten J, Bromley RL, Taylor J, Adab N, Kini U, Baker GA (2009) The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav 14(1):197–201CrossRefPubMedGoogle Scholar
  10. 10.
    Wide K, Henning E, Tomson T, Winbladh B (2002) Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr 91(4):409–414CrossRefPubMedGoogle Scholar
  11. 11.
    Veiby G, Daltveit AK, Schjolberg S, Stoltenberg C, Øyen A, Vollset SE et al (2013) Exposure to antiepileptic drugs in utero and child development—a prospective population-based study. Epilepsia 54(8):1462–1472PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Veiby G, Engelsen BA, Gilhus NE (2013) Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol 70(11):1367–1374Google Scholar
  13. 13.
    Rauchenzauner M, Ehrensberger M, Prieschl M, Kapelari K, Bergmann M, Walser G et al (2013) Generalized tonic-clonic seizures and antiepileptic drugs during pregnancy-a matter of importance for the baby? J Neurol 260(2):484–488CrossRefPubMedGoogle Scholar
  14. 14.
    Cantwell R, Clutton-Brock T, Cooper G, Dawson A, Drife J, Garrod D et al (2011) Saving mothers’ lives: reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 118(Suppl 1):1–203PubMedGoogle Scholar
  15. 15.
    Chen YH, Chiou HY, Lin HC, Lin HL (2009) Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol 66(8):979–984CrossRefPubMedGoogle Scholar
  16. 16.
    Teramo K, Hiilesmaa V, Bardy A, Saarikoski S (1979) Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 7(1):3–6CrossRefPubMedGoogle Scholar
  17. 17.
    Borthen I, Eide MG, Veiby G, Daltveit AK, Gilhus NE (2009) Complications during pregnancy in women with epilepsy: population-based cohort study. BJOG 116(13):1736–1742CrossRefPubMedGoogle Scholar
  18. 18.
    EURAP Study Group (2006) Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 66(3):354–360Google Scholar
  19. 19.
    Skjaerven R, Gjessing HK, Bakketeig LS (2000) Birthweight by gestational age in Norway. Acta Obstet Gynecol Scand 79(6):440–449CrossRefPubMedGoogle Scholar
  20. 20.
    Abuelo D (2007) Microcephaly syndromes. Semin Pediatr Neurol 14(3):118–127CrossRefPubMedGoogle Scholar
  21. 21.
    Almgren M, Kallen B, Lavebratt C (2009) Population-based study of antiepileptic drug exposure in utero-influence on head circumference in newborns. Seizure 18(10):672–675CrossRefPubMedGoogle Scholar
  22. 22.
    Barker DJ (2006) Adult consequences of fetal growth restriction. Clin Obstet Gynecol 49(2):270–283CrossRefPubMedGoogle Scholar
  23. 23.
    Cheong JL, Hunt RW, Anderson PJ, Howard K, Thompson DK, Wang HX et al (2008) Head growth in preterm infants: correlation with magnetic resonance imaging and neurodevelopmental outcome. Pediatrics 121(6):e1534–e1540CrossRefPubMedGoogle Scholar
  24. 24.
    Saenger P, Czernichow P, Hughes I, Reiter EO (2007) Small for gestational age: short stature and beyond. Endocr Rev 28(2):219–251CrossRefPubMedGoogle Scholar
  25. 25.
    Tomson T, Battino D (2012) Teratogenic effects of antiepileptic drugs. Lancet Neurol 11(9):803–813CrossRefPubMedGoogle Scholar
  26. 26.
    Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C (2012) The FDA’s assessment of two drugs for chronic weight management. N Engl J Med 367(17):1577–1579CrossRefPubMedGoogle Scholar
  27. 27.
    Ornoy A, Zvi N, Arnon J, Wajnberg R, Shechtman S, Diav-Citrin O (2008) The outcome of pregnancy following topiramate treatment: a study on 52 pregnancies. Reprod Toxicol 25(3):388–389CrossRefPubMedGoogle Scholar
  28. 28.
    Pickrell WO, Lacey AS, Thomas RH, Smith PE, Rees MI (2013) Weight change associated with antiepileptic drugs. J Neurol Neurosurg Psychiatry 84(7):796–799Google Scholar
  29. 29.
    Molgaard-Nielsen D, Hviid A (2011) Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305(19):1996–2002CrossRefPubMedGoogle Scholar
  30. 30.
    Holmes LB, Hernandez-Diaz S (2012) Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Birth Defects Res A Clin Mol Teratol 94(8):599–606CrossRefPubMedGoogle Scholar
  31. 31.
    Jentink J, Loane MA, Dolk H, Barisic I, Garne E, Morris JK et al (2010) Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 362(23):2185–2193CrossRefPubMedGoogle Scholar
  32. 32.
    Vajda FJ, O’Brien TJ, Lander CM, Graham J, Roten A, Eadie MJ (2013) Teratogenesis in repeated pregnancies in antiepileptic drug-treated women. Epilepsia 54(1):181–186CrossRefPubMedGoogle Scholar
  33. 33.
    Kini U, Lee R, Jones A, Smith S, Ramsden S, Fryer A et al (2007) Influence of the MTHFR genotype on the rate of malformations following exposure to antiepileptic drugs in utero. Eur J Med Genet 50(6):411–420CrossRefPubMedGoogle Scholar
  34. 34.
    Wlodarczyk BJ, Palacios AM, Chapa CJ, Zhu H, George TM, Finnell RH (2011) Genetic basis of susceptibility to teratogen induced birth defects. Am J Med Genet C Semin Med Genet 157(3):215–226CrossRefGoogle Scholar
  35. 35.
    Cassina M, Salviati L, Di GE, Clementi M (2012) Genetic susceptibility to teratogens: state of the art. Reprod Toxicol 34(2):186–191CrossRefPubMedGoogle Scholar
  36. 36.
    Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S (2011) Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 68(10):1275–1281CrossRefPubMedGoogle Scholar
  37. 37.
    Hoff JM, Daltveit AK, Gilhus NE (2007) Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 14(1):38–43CrossRefPubMedGoogle Scholar
  38. 38.
    Skomsvoll J, Ostensen M, Baste V, Irgens L (2002) Validity of a rheumatic disease diagnosis in the Medical Birth Registry of Norway. Acta Obstet Gynecol Scand 81(9):831–834CrossRefPubMedGoogle Scholar
  39. 39.
    Borthen I, Eide M, Daltveit A, Gilhus N (2011) Obstetric outcome in women with epilepsy: a hospital-based, retrospective study. BJOG 118(8):956–965CrossRefPubMedGoogle Scholar
  40. 40.
    Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K (2008) Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol 65(5):653–660PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Gyri Veiby
    • 1
    • 2
  • Anne Kjersti Daltveit
    • 3
    • 4
  • Bernt A. Engelsen
    • 1
    • 2
  • Nils Erik Gilhus
    • 1
    • 2
  1. 1.Department of Clinical Medicine, Section for NeurologyUniversity of BergenBergenNorway
  2. 2.Department of NeurologyHaukeland University HospitalBergenNorway
  3. 3.Department of Global Health and Primary CareUniversity of BergenBergenNorway
  4. 4.Medical Birth Registry of Norway, Division of EpidemiologyNorwegian Institute of Public HealthBergenNorway

Personalised recommendations